Paper36701088
Apheresis: What Should a Clinician Know?
Parhofer KG. Curr Atheroscler Rep, 2023. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Apheresis: What Should a Clinician Know? Papers, record 36701088. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36701088
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hyperlipoproteinemia Type II | Major topic |
| Homozygous Familial Hypercholesterolemia | Major topic |
| Blood Component Removal | Major topic |
| Humans | |
| Cholesterol, LDL | |
| Lipoprotein(a) |
Source PubMed
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27572070 | Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. | Eur Heart J | 2016 | https://conductscience.org/library/papers/27572070 | PubMed |
| 2 | 35718549 | Effect of Lipoprotein Apheresis on Progression of Carotid Intima-Media Thickness in Patients with Severe Hypercholesterolemia. | Am J Cardiol | 2022 | https://conductscience.org/library/papers/35718549 | PubMed |
| 3 | 34472586 | Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. | Eur Heart J | 2021 | https://conductscience.org/library/papers/34472586 | PubMed |
| 4 | 48833 | Plasma exchange in the management of homozygous familial hypercholesterolaemia. | Lancet | 1975 | https://conductscience.org/library/papers/48833 | PubMed |
| 5 | 7898227 | Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. | Lancet | 1995 | https://conductscience.org/library/papers/7898227 | PubMed |
| 6 | 24056686 | Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. | Circulation | 2013 | https://conductscience.org/library/papers/24056686 | PubMed |
| 7 | 21834078 | Lipid apheresis, indications, and principles. | J Clin Apher | 2011 | https://conductscience.org/library/papers/21834078 | PubMed |
| 8 | 23889507 | Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events? | Artif Organs | 2014 | https://conductscience.org/library/papers/23889507 | PubMed |
| 9 | 31041550 | Current Role of Lipoprotein Apheresis. | Curr Atheroscler Rep | 2019 | https://conductscience.org/library/papers/31041550 | PubMed |
| 10 | 20935563 | Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. | Curr Opin Lipidol | 2010 | https://conductscience.org/library/papers/20935563 | PubMed |
| 11 | 30058841 | From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. | Eur J Prev Cardiol | 2018 | https://conductscience.org/library/papers/30058841 | PubMed |
| 12 | 30611543 | Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a). | Pathology | 2019 | https://conductscience.org/library/papers/30611543 | PubMed |
| 13 | 18371971 | Recommendations for the use of LDL apheresis. | Atherosclerosis | 2008 | https://conductscience.org/library/papers/18371971 | PubMed |
| 14 | 31504418 | 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. | Eur Heart J | 2020 | https://conductscience.org/library/papers/31504418 | PubMed |
| 15 | 31280466 | PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice. | Drugs Real World Outcomes | 2019 | https://conductscience.org/library/papers/31280466 | PubMed |
| 16 | 31753721 | Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease. | J Clin Lipidol | 2019 | https://conductscience.org/library/papers/31753721 | PubMed |
| 17 | 9874053 | Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. | Am J Cardiol | 1998 | https://conductscience.org/library/papers/9874053 | PubMed |
| 18 | 29096836 | Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis. | Atheroscler Suppl | 2017 | https://conductscience.org/library/papers/29096836 | PubMed |
| 19 | 1827976 | Immunosorbent for selective removal of lipoprotein (a) from human plasma: in vitro study. | Artif Organs | 1991 | https://conductscience.org/library/papers/1827976 | PubMed |
| 20 | 26889050 | Lipoprotein apheresis to treat elevated lipoprotein (a). | J Lipid Res | 2016 | https://conductscience.org/library/papers/26889050 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42461299 | [Austrian lipid consensus : Interdisciplinary evidence-based recommendations on prevention and treatment of lipid-associated diseases from 15 medical specialist societies]. | Wien Klin Wochenschr | 2026 | https://conductscience.org/library/papers/42461299 | PubMed |
| 42124773 | Lipoprotein(a): Role in Cardiovascular Risk and Advances in Novel Therapeutics. | Cureus | 2026 | https://conductscience.org/library/papers/42124773 | PubMed |
| 39769362 | Reduced Oxidative Susceptibility of Lp(a) and LDL Fractions as a Pleiotropic Effect of Lipoprotein Apheresis in Patients with Elevated Lp(a) and ASCVDs. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39769362 | PubMed |
| 38436784 | Updates on Non-Statin LDL-Lowering Therapy. | Curr Cardiol Rep | 2024 | https://conductscience.org/library/papers/38436784 | PubMed |
| 37799590 | Case report: lipoprotein apheresis reduces the risk of cardiovascular events and prolongs pregnancy in a woman with severely elevated lipoprotein(a), cardiovascular disease, and a high risk of preeclampsia. | Front Med (Lausanne) | 2023 | https://conductscience.org/library/papers/37799590 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| APOB | 338 | PubTator's text mining | https://conductscience.org/library/genes/338 | NCBI Gene |
| LPA | 4018 | PubTator's text mining | https://conductscience.org/library/genes/4018 | NCBI Gene |
| PCSK9 | 255738 | PubTator's text mining | https://conductscience.org/library/genes/255738 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36701088
GET https://conductscience.org/api/papers/v1/36701088/references?page=2